Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stromal Vascular Fraction for Severe COVID-19 Pulmonary Disease
RBR-2tfxtnzRecruiting
- Sponsor
- Escola Paulista de Medicina
- Start
- Mar 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of autologous adipose stromal vascular fraction in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Escola Paulista de Medicina. Started Mar 2021; status: recruiting.
02
Drugs
autologous adipose stromal vascular fraction
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-2tfxtnz.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2tfxtnz.